Bris­tol My­ers snares an­oth­er ap­proval from the old Cel­gene pipeline, nab­bing an over­looked OK

Bris­tol My­ers Squibb has got­ten an­oth­er ap­proval from the old Cel­gene pipeline yes­ter­day, this time for a once low-pro­file com­pound.

The FDA green-light­ed Onureg, an oral drug pre­vi­ous­ly known as CC-486. It’s chem­i­cal­ly known as azac­i­ti­dine — the same com­pound that in its IV form, brand­ed as Vi­daza, has long been used to treat acute myeloid leukemia and myelodys­plas­tic syn­dromes. For Bris­tol My­ers, it marks the sec­ond ma­jor ap­proval since the Cel­gene merg­er was com­plet­ed, af­ter the mul­ti­ple scle­ro­sis drug Zeposia was OK’d ear­li­er this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.